FIT Trial: A Randomized Multi-Site Intervention to Increase Adherence to Alpha Interferon for Melanoma

2.50
Hdl Handle:
http://hdl.handle.net/10755/165304
Category:
Abstract
Type:
Presentation
Title:
FIT Trial: A Randomized Multi-Site Intervention to Increase Adherence to Alpha Interferon for Melanoma
Author(s):
Schwartz, Anna
Author Details:
Anna Schwartz, PhD, ARNP, University of Washington, Seattle, Washington, USA
Abstract:
Stage III melanoma is a serious, challenging cancer to treat. Interferon-alpha (IFN) is an efficacious treatment with severe, treatment limiting side-effects. Patients who are not able to receive full dose treatment are at greater risk for recurrence and death. The purpose was to determine the effects of exercise + methylphenidate EX+MPD) on fatigue, quality of life (QOL), and IFN tolerance. Primary objective: examine differences IFN patients randomized to EX+MPD or exercise-alone (EX) on: fatigue, QOL, functional ability, and cognitive function. The secondary aims: to determine the percent who 1) adhered to EX; 2) experienced methylphenidate toxicity ; 3) adhered to treatment. IFN is associated with severe, dose-limiting toxicities, especially fatigue. Even when changing from induction to maintenance phase, toxicities continue to effect adherence. To improve tolerance of IFN, interventions are needed to minimize side effects, improve QOL, and ultimately long-term outcomes. Research suggests aerobic exercise reduces fatigue and improves QOL, however, no randomized trials have examined EX+MPD on fatigue, QOL, and cognition in melanoma patients. Two-arm, randomized trial tested EX+MPD vs EX on fatigue, QOL, functional ability and cognition of patients with melanoma receiving IFN (> 5 million units). 32 subjects were followed 4-months from IFN initiation. All subjects exercised aerobically 3-4 days/week, 15-30 minutes at a moderate intensity. Methylphenidate (10mg po qam) began after 1-week of therapy. Reliable and valid measures, of fatigue, QOL, functional ability and cognition were obtained every month. Descriptive statistics and ANOVA were used to describe the sample and differences between groups. Fatigue was lower in EX+MPD than EX (difference=2.1, p<.05). No differences QOL between EX and EX+MPD. Functional ability improved (EX 5.6%, EX+MPD 6.4%, p>.05). Cognitive function was stable EX+MPD, and declined for EX (difference=2.1, p>.05). 88% (N=14) adhered to EX, 75% (N=12) adhered to EX+MPD. Clinically important differences in fatigue, functional ability and cognition were observed in EX+MPD. EX+MPD may be an important intervention to improve tolerance for IFN and ultimately increase melanoma survival.
Repository Posting Date:
27-Oct-2011
Date of Publication:
27-Oct-2011
Conference Date:
2005
Conference Name:
30th Annual Oncology Nursing Society Congress
Conference Host:
Oncology Nursing Society
Conference Location:
Orlando, Florida, USA
Sponsors:
Funding Sources: Funded by the ONS Foundation through an unrestricted grant from Schering Oncology Biotech and Integrated Therapeutics Group.
Note:
This is an abstract-only submission. If the author has submitted a full-text item based on this abstract, you may find it by browsing the Virginia Henderson Global Nursing e-Repository by author. If author contact information is available in this abstract, please feel free to contact him or her with your queries regarding this submission. Alternatively, please contact the conference host, journal, or publisher (according to the circumstance) for further details regarding this item. If a citation is listed in this record, the item has been published and is available via open-access avenues or a journal/database subscription. Contact your library for assistance in obtaining the as-published article.

Full metadata record

DC FieldValue Language
dc.type.categoryAbstracten_US
dc.typePresentationen_GB
dc.titleFIT Trial: A Randomized Multi-Site Intervention to Increase Adherence to Alpha Interferon for Melanomaen_GB
dc.contributor.authorSchwartz, Annaen_US
dc.author.detailsAnna Schwartz, PhD, ARNP, University of Washington, Seattle, Washington, USAen_US
dc.identifier.urihttp://hdl.handle.net/10755/165304-
dc.description.abstractStage III melanoma is a serious, challenging cancer to treat. Interferon-alpha (IFN) is an efficacious treatment with severe, treatment limiting side-effects. Patients who are not able to receive full dose treatment are at greater risk for recurrence and death. The purpose was to determine the effects of exercise + methylphenidate EX+MPD) on fatigue, quality of life (QOL), and IFN tolerance. Primary objective: examine differences IFN patients randomized to EX+MPD or exercise-alone (EX) on: fatigue, QOL, functional ability, and cognitive function. The secondary aims: to determine the percent who 1) adhered to EX; 2) experienced methylphenidate toxicity ; 3) adhered to treatment. IFN is associated with severe, dose-limiting toxicities, especially fatigue. Even when changing from induction to maintenance phase, toxicities continue to effect adherence. To improve tolerance of IFN, interventions are needed to minimize side effects, improve QOL, and ultimately long-term outcomes. Research suggests aerobic exercise reduces fatigue and improves QOL, however, no randomized trials have examined EX+MPD on fatigue, QOL, and cognition in melanoma patients. Two-arm, randomized trial tested EX+MPD vs EX on fatigue, QOL, functional ability and cognition of patients with melanoma receiving IFN (&gt; 5 million units). 32 subjects were followed 4-months from IFN initiation. All subjects exercised aerobically 3-4 days/week, 15-30 minutes at a moderate intensity. Methylphenidate (10mg po qam) began after 1-week of therapy. Reliable and valid measures, of fatigue, QOL, functional ability and cognition were obtained every month. Descriptive statistics and ANOVA were used to describe the sample and differences between groups. Fatigue was lower in EX+MPD than EX (difference=2.1, p&lt;.05). No differences QOL between EX and EX+MPD. Functional ability improved (EX 5.6%, EX+MPD 6.4%, p&gt;.05). Cognitive function was stable EX+MPD, and declined for EX (difference=2.1, p&gt;.05). 88% (N=14) adhered to EX, 75% (N=12) adhered to EX+MPD. Clinically important differences in fatigue, functional ability and cognition were observed in EX+MPD. EX+MPD may be an important intervention to improve tolerance for IFN and ultimately increase melanoma survival.en_GB
dc.date.available2011-10-27T12:16:08Z-
dc.date.issued2011-10-27en_GB
dc.date.accessioned2011-10-27T12:16:08Z-
dc.conference.date2005en_US
dc.conference.name30th Annual Oncology Nursing Society Congressen_US
dc.conference.hostOncology Nursing Societyen_US
dc.conference.locationOrlando, Florida, USAen_US
dc.description.sponsorshipFunding Sources: Funded by the ONS Foundation through an unrestricted grant from Schering Oncology Biotech and Integrated Therapeutics Group.-
dc.description.noteThis is an abstract-only submission. If the author has submitted a full-text item based on this abstract, you may find it by browsing the Virginia Henderson Global Nursing e-Repository by author. If author contact information is available in this abstract, please feel free to contact him or her with your queries regarding this submission. Alternatively, please contact the conference host, journal, or publisher (according to the circumstance) for further details regarding this item. If a citation is listed in this record, the item has been published and is available via open-access avenues or a journal/database subscription. Contact your library for assistance in obtaining the as-published article.-
All Items in this repository are protected by copyright, with all rights reserved, unless otherwise indicated.